0001437749-14-011906.txt : 20140627 0001437749-14-011906.hdr.sgml : 20140627 20140626160739 ACCESSION NUMBER: 0001437749-14-011906 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140624 FILED AS OF DATE: 20140626 DATE AS OF CHANGE: 20140626 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Furiex Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001484478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271197863 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3900 PARAMOUNT PARKWAY STREET 2: SUITE 150 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919-456-7800 MAIL ADDRESS: STREET 1: 3900 PARAMOUNT PARKWAY STREET 2: SUITE 150 CITY: MORRISVILLE STATE: NC ZIP: 27560 FORMER COMPANY: FORMER CONFORMED NAME: PPD Therapeutics, Inc. DATE OF NAME CHANGE: 20100218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: COVINGTON PAUL S CENTRAL INDEX KEY: 0001181153 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34641 FILM NUMBER: 14942809 MAIL ADDRESS: STREET 1: 3116 BRAEMAR DRIVE CITY: WILMINGTON STATE: NC ZIP: 28401 4 1 rdgdoc.xml FORM 4 X0306 4 2014-06-24 0001484478 Furiex Pharmaceuticals, Inc. FURX 0001181153 COVINGTON PAUL S C/O FURIEX PHARMACEUTICALS, INC., 3900 PARAMOUNT PARKWAY, SUITE 150 MORRISVILLE NC 27560 1 Senior VP-Clinical Operations Common Stock 2014-06-24 4 M 0 10368 17.80 A 32891 D Common Stock 2014-06-24 4 S 0 10368 104.12 D 22523 D Stock Options (to buy) 17.80 2014-06-24 4 M 0 10368 0 D 2022-02-24 Common Stock 10368 0 D Stock Options (to buy) 15.0000 2021-05-09 Common Stock 26000 26000 D Stock Options (to buy) 13.1600 2021-10-03 Common Stock 37944 37944 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.01 to $104.28, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. All options became 100% vested on June 11, 2014 in connection with the Agreement and Plan of Merger dated as of April 27, 2014 by and among Forest Laboratories, Inc., Royal Empress, Inc. and Furiex Pharmaceuticals, Inc. /s/ Paul S. Covington 2014-06-26